Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 804 of 6351
-
Can a home eye scanner replace frequent doctor visits for wet AMD?
Disease control OngoingHome optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
Phase 3 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for mesothelioma patients: experimental combo enters final testing
Disease control OngoingThis is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleur…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New Three-Drug cocktail takes on tough colorectal cancer
Disease control Recruiting nowThe primary aim of phase II CEIL study is to evaluate the efficacy of cetuximab and envafolimab plus mFOLFOXIRI versus cetuximab plus mFOLFOX6 as first line treatment of patients with initially unresectable and previously untreated RAS/BRAF wild-type, MSS, left-side metastatic co…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New contrast mammography could spot breast cancer recurrence earlier
Diagnosis Recruiting nowThis is a prospective clinical trial that will examine if biennial contrast-enhanced mammography added to annual 3D mammography (tomosynthesis) substantially improves breast cancer detection with minimal increase in false-positives, in women with a personal history of breast canc…
Sponsor: Wendie Berg • Aim: Diagnosis
Last updated Aug 21, 2026 00:00 UTC
-
New drug cocktail shows promise against tough esophageal cancer
Disease control CompletedThis is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with inoperable locally advanced or metastatic esophageal squamou…
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New shot shows promise for tough eczema cases
Disease control CompletedThis is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical pre…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could your own immune cells beat advanced melanoma?
Disease control Completed20 participants are expected to be enrolled for the Phase Ib clinical trial,this trail is expected to be finished in 20 months.
Phase 1/2 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug duo aims to halt deadly blood cancer progression
Disease control Recruiting nowThe purpose of this research study is to look at how safe and useful a drug called azacitidine in combination with a drug called venetoclax, is in people with accelerated or blast phase BRC-ABL negative myeloproliferative neoplasms.
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Triple immunotherapy attack shows promise for tough skin cancer
Disease control OngoingThis phase II trial tests how well a combination of three immunotherapy drugs work for patients with Merkel cell carcinoma that has spread to lymph nodes and/or distant parts of the body and cannot be treated with surgery (advanced or metastatic MCC) and grew despite prior PD-(L)…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingThe purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo. Vitiligo causes white patches on your skin when the cells that give your skin color are destroyed. Nonsegmental means that it…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Hard-to-Treat brain cancer: targeted radiation trial launches
Disease control Recruiting nowThis will be an open-label, single-arm, national phase 1/2 therapeutic study to evaluate the safety, tolerability, and preliminary efficacy of \[90Y\]Y-PentixaTher (\[90Y\]Y-PTT) for the treatment of recurrent or refractory primary or isolated secondary central nervous system (CN…
Phase 1/2 • Sponsor: Pentixapharm AG • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control OngoingThe purpose of this study is to learn if the study drug, \[225Ac\]Ac-PSMA-R2, is safe and tolerable, and has anti-tumor activity in treated patients.
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Smart blood pressure monitoring may shield kidneys during robotic surgery
Prevention CompletedIt is a single-center randomized controlled trial that aims to figure out the effect of the hypotension prediction index (HPI) on the prevention of acute kidney injury (AKI) after robot-assisted urological surgery. The primary hypothesis is that HPI software guidance prevents pos…
Sponsor: Ewha Womans University Mokdong Hospital • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
New combo therapy aims to boost immune attack on HPV-Positive throat cancer
Disease control OngoingBackground: Cancers in and around the mouth associated with human papilloma virus (HPV) are common. Two treatments (the drug pembrolizumab and the HPV vaccine PRGN-2009) have been shown to work well when used individually against these cancers. Researchers want to find out if th…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill combo aims to slow kidney decline in High-Risk patients
Disease control OngoingThis is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug combo aims to fight recurrent cervical cancer
Disease control Recruiting nowObjective: To explore the efficacy, safety and tolerability of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in patients with recurrent or metastatic cervical cancer and other gynecological malignancies, and to further explore the optimal dose and mode of combination.
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Simple malaria test in early pregnancy could save newborns
Prevention OngoingThe purpose of the INTREPiD study is to compare 1st trimester screening for malaria parasites with a high-sensitivity malaria rapid diagnostic test followed by treatment of test-positive women with artemether-lumefantrine (AL) against usual antenatal care on a composite adverse p…
Phase 4 • Sponsor: Duke University • Aim: Prevention
Last updated Jun 27, 2026 12:31 UTC
-
Magnets may offer new way to treat obesity and diabetes
Disease control OngoingThe purpose of this clinical research study is to evaluate the feasibility of the GT Metabolic Solutions Magnet System, GJ Biofragmentable ("MagGJ System") for creation of a side-to-side anastomosis for gastro-ileal or gastro-jejunal diversion in obese adults.
Sponsor: GT Metabolic Solutions, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New psoriasis pill shows promise in large trial
Disease control CompletedThe main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Engineered immune cells get a metabolic boost to fight blood cancers
Disease control Recruiting nowThis is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL…
Phase 1/2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC